Canavan Disease (CD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Canavan disease (CD) is a genetic degenerative brain disease caused by a lack of the enzyme aspartoacylase (ASPA). N-acetylaspartic acid builds up in the brain and other body parts when ASPA activity is lost. CD is diagnosed by detecting elevated NAA in urine, blood, or the brain by proton MR spectroscopy and ASPA mutation analysis. Insufficient myelination and progressive spongy degeneration of the brain's white matter characterize the disease histologically. While not all Canavan disease (CD) patients had epilepsy in their early years, seizure prevalence increased over the first decade, with all CD patients having seizures by ten. Multiple antispasmodic or antiepileptic drugs are frequently required to treat neurological symptoms such as seizures and spasticity. Canavan disease (CD) is caused by mutations in the ASPA gene (17p13.3), which codes for the aspartoacylase enzyme. Numerous mutations have been discovered, and enzymatic activity is either low or non-existent as a result.

·       The incidence of Canavan disease (CD) varies between 1 to 1.5 cases per 100,000 birth population in the USA.

 

Thelansis’s “Canavan Disease (CD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Canavan Disease (CD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Canavan Disease (CD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Canavan Disease (CD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Canavan Disease (CD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Canavan Disease (CD), Canavan Disease (CD) market outlook, Canavan Disease (CD) competitive landscape, Canavan Disease (CD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)